The JADE Mono-2 study in adolescent and adult patients with atopic dermatitis (AD) investigated the efficacy and safety of abrocitinib. The results demonstrated significant advantages in clinical signs and symptoms over placebo [1,2].
The randomised, controlled, double-blind, phase 3 trial included 391 patients aged ≥12 years with moderate-to-severe AD from 115 centres worldwide and was presented by Dr Melinda Gooderham (Queen’s University and Probity Medical Research, Canada). Patients with prior dupilumab failure were not excluded from the trial. All participants had AD for ≥1 year, and topical medication had not been successful. The primary endpoints of the trial were the rate of patients reaching an Eczema Area and Severity Index (EASI) score of ≥75 at week 12, or an Investigator’s Global Assessment (IGA) of 0 or 1 (clear or almost clear skin) with an improv...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis Next Article
IL-17A and IL-17F blockade remarkably effective in psoriasis »